ADC-2403

ADC-2403 is an antibody-drug conjugate (ADC) initially developed by Hangzhou Adcoris Biopharmacy. It is currently in the discovery stage of development and is being investigated for the treatment of neoplasms (cancers). As an ADC, it consists of a monoclonal antibody linked to a cytotoxic drug payload via a chemical linker. The mechanism of action involves selective binding to target antigens on cancer cells, internalization into the cell, and subsequent release of the cytotoxic agent to induce cancer cell death while minimizing damage to healthy tissues[1][6][8]. No specific target antigen or payload details have been disclosed publicly as of now.